核苷之间的恩替卡韦治疗的评估（T）IDE初治患者摩洛哥慢性

StephenW

BMJ Open Gastro 2016; 3:e000081 doi:10.1136/bmjgast-2016-000081
An evaluation of entecavir treatment among nucleos(t)ide-naïve Moroccan patients with chronic hepatitis B
Amal Chakkor1, Fedoua Rouibaa1, Safiaa Elaboudi2, Aziz Aourarh1,
Author Affiliations
1Gastroenterology Unit “I”, Mohamed V Military Hospital, Mohamed V University, Rabat, Morocco
2Medecine “C” Unit, Ibn Sina University Hospital, Mohamed V University, Rabat, Morocco
Received:
27 January 2016
Accepted:
21 March 2016
Published Online:
26 April 2016

Abstract
Objective

To analyse the efficacy and safety of entecavir (ETV) treatment in nucleos(t)ide (NUC)-naïve Moroccan patients with chronic hepatitis B.
Methods

We retrospectively analysed 41 NUT-naïve Moroccan patients with chronic hepatitis B who received ETV 0,5 mg/day monotherapy for at least 3 months, of whom 3 were HBV envelope antigen (HbeAg) positive and 38 were HBeAg negative. The primary end point was the proportion of patients achieving virological response. Secondary end points included biochemical response (alanine transaminase (ALT) normalisation), serological response (HbeAg and HBV surface antigen (HBsAg) loss or seroconversion) and safety.
Results

The median follow-up duration was 74 weeks (48–144 weeks) and mean age was 43.8 years. Of 41 patients, 6 were primary non-responders and 2 achieved partial virological response at week 48, whereas 35 achieved undetectable hepatitis B virus (HBV) DNA at month 12. Viral suppression was maintained in 97.6% of patients after 3 years of ETV treatment. One patient experienced a virological breakthrough at month 12 of treatment. ALT normalisation occurred in 100% of the patients after 1 year of treatment. Only three patients in our study were HbeAg positive, of whom one has experienced seroconversion at month 12 of treatment. However, HBsAg loss or seroconversion was not achieved during the period of the study. No serious adverse event was reported.
Conclusions

These preliminary results showed that ETV is a safe and potent inhibitor of HBV in NUC-naïve Moroccan patients, but we need to observe more patients for a longer period of time, in order to assess the long-term effectiveness, safety, resistance profile and predictive factors for virological and serological response of ETV.
Keywords: HEPATITIS B, TOLERANCE, ANTIVIRAL THERAPY

StephenW

BMJ打开胃2016年; 3：e000081 DOI：10.1136 / bmjgast-2016-000081
核苷之间的恩替卡韦治疗的评估（T）IDE初治患者摩洛哥慢性乙型肝炎
阿迈勒Chakkor1，Fedoua Rouibaa1，Safiaa Elaboudi2，阿齐兹Aourarh1，
作者机构
1Gastroenterology单位“I”，穆罕默德五世军事医院，穆罕默德五世大学，拉巴特，摩洛哥
2Medecine“C”股，伊本西纳大学医院，穆罕默德五世大学，拉巴特，摩洛哥
收稿日期：
2016年1月27日
公认：
2016年3月21日
在线发布时间：
2016年4月26日

抽象
目的

分析在核苷（酸）的IDE（NUC）-naïve摩洛哥治疗慢性乙型肝炎的疗效和恩替卡韦（ETV）治疗的安全性
方法

我们回顾性分析41 NUT初治患者摩洛哥与谁收到ETV 0.5毫克/天，单药治疗至少3个月的慢性乙肝，其中3人是乙肝病毒包膜抗原（HBeAg）阳性，38例HBeAg阴性。主要终点是患者达到病毒学应答的比例。次要终点包括生化反应（丙氨酸转氨酶（ALT）正常化），血清学应答（HBeAg和HBV表面抗原（HBsAg）转阴或血清转化）和安全性。
结果

中位随访时间为74周（48-144周）和平均年龄为43.8年。 41名患者中，6为原发性无应答者和2达到48周部分病毒学应答，而35个月时达到不可检测乙肝病毒（HBV）DNA 12.病毒抑制被保持在患者97.6％3年后ETV治疗的。 1例患者在治疗12个月病毒学突破。 ALT复常发生在100％的患者治疗1年后。在我们的研究中只有三例患者HBeAg阳性，其中一人已经在治疗12个月经历了血清学转换。然而，在研究期间没有实现HBsAg转阴或血清学转换。据报道无严重不良事件。
结论

这些初步结果表明，ETV是乙肝病毒的NUC-天真摩洛哥患者安全和有效的抑制剂，但是我们需要观察更多的患者的时间更长的时间，以评估长期有效性，安全性，电阻档和预测因素病毒学和ETV的血清学应答。
关键词：乙型肝炎，宽容，抗病毒治疗

儒者也

研究时间短，病例也不多？

StephenW

回复 儒者也 的帖子

同意，仅仅是为了信息